סימוביל 40 מ"ג

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

SIMVASTATIN 40 MG

Disponibbli minn:

MERCK SHARP & DOHME ISRAEL LTD

Kodiċi ATC:

C10AA01

Għamla farmaċewtika:

TABLETS

Rotta amministrattiva:

PER OS

Manifatturat minn:

MERCK SHARP & DOHME B.V, HOLLAND

Grupp terapewtiku:

SIMVASTATIN

Indikazzjonijiet terapewtiċi:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simovil is indicated to: Reduce the risk of total mortality by reducing coronary death; Reduce the risk of non-fatal myocardial infarction; Reduce the risk for undergoing myocardial revascularization procedures; Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simovil is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simovil therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simovil is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglycerid

Data ta 'l-awtorizzazzjoni:

2013-01-01